Adverse reactions to antirretroviral drugs in patients with the human inmunodeficiency virus

Authors

  • Neity Mendo Alcolea Universidad de Ciencias Médicas. Santiago de Cuba
  • Eduardo de Jesús Mesa Perez Universidad de Ciencias Médicas. Santiago de Cuba
  • Rafael Neyra Barrios Universidad de Ciencias Médicas. Santiago de Cuba
  • Lázaro Berenguer Gournaluses Universidad de Ciencias Médicas. Santiago de Cuba
  • Graciela Nieto Muñiz Universidad de Ciencias Médicas. Santiago de Cuba

Keywords:

HIV, antirretroviral drugs, adverse reaction, pharmacosurveillance, primary health care

Abstract

A descriptive and cross sectional study of 40 patients with HIV belonging to the Teaching Polyclinic "Frank País García" in Santiago de Cuba was carried out with the aim of identifying the adverse reactions to antirretroviral drugs during the first semester of 2018. Most of the notifications were carried out by specialists in Comprehensive General Medicine (61,4%) in the case material, followed by those of Internal Medicine and  Licentiate in Nursing (8,8 and 17,6%, respectively); also, among the predominant adverse effects there were nauseas, migraine and sickness, fundamentally with the therapeutic schemes constituted by lamivudina-zidovudina-nevirapina and zidovudina-nevirapina-efavirenz.  It is concluded that during antirretroviral treatment most of these reactions were classified as definitive, independently of the prescribed therapeutic scheme and the concomitant diseases.

Downloads

Download data is not yet available.

References

1. Nuevos avances en investigación y desarrollo sobre el VIH, 2014 [citado 18/02/2018]. Disponible en: http://www.unaids.org/es/resources/presscentre/featurestories/2014/march/20140310salim
2. Plan estratégico nacional para la prevención y el control de las ITS y el VIH/sida, 2014-2018 [citado 18/02/2018]. Disponible en: http://files.sld.cu/sida/files/2014/03/pen-primera-parte.pdf
3. World Health Organization. Consolidates guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public approach. Geneva: WHO; 2013.
4. Morón Rodríguez F, Levy Rodríguez M, Álvarez Corredera M, Borroto Regalado R, Cruz Barrios MA, Salazar Domínguez LE, et al. La Habana: Editorial Ciencias Médicas; 2002.
5. Haile DB, Ayen WY, Tiwari P. Prevalence and assessment of factors contributing to adverse drug reactions in wards of a tertiary care hospital, India. Ethiop J Health Sci. 2013; 23(1):39-48.
6. Antiretroviral Therapy Cohort Collaboration (ART-CC), Vandenhende MA, Ingle S, May M, Chene G, Zangerle R, et al. Impact of low-level viremia on clinical and virological outcomes in treated HIV-1-infected patients. AIDS. 2015;29(3):373-83.
7. Szlejf C, Farfel JM, Curiati JA, de Barros Couto E, Jacob Filho W, Soares Azevedo R. Medical adverse events in elderly hospitalized patients: a prospective study. Clinics (Sao Paulo). 2012; 67 (11):1247-52.
8. Wright ST, Petoumenos K, Boyd M, Carr A, Downing S, O'Connor CC, et al. Ageing and long-term CD4 cell count trends in HIV-positive patients with 5 years or more combination antiretroviral therapy experience. HIV Med. 2013; 14(4):208-216.
9. Diagnoses of HIV infection in the United States and dependent areas. HIV Surveillance Report. 2014 [citado 15/02/2018]; 26. Disponible en: https://www.cdc.gov/hiv/pdf/library/reports/surveillance/cdc-hiv-surveillance-report-2014-vol-26.pdf
10. Zheng Y, Hughes MD, Lockman S, Benson CA, Hosseinipour MC, Campbell TB, et al. Antiretroviral therapyand efficacy after virologic failure on first-line boosted protease inhibitor regimens. Clin Infec Dis. 2014; 59(6):888-96.
11. Berthoux E, Dufour C, Raharisondraibe E, Bonnefoy M. Preventable drug events in acute geriatric unit. Geriatr Psicol Neuropsychiatr Vieil. 2013;11(1):15-20.
12. Wallet MA, Buford TW, Joseph AM, Sankuratri M, Leeuwenburgh C, Pahor M, et al. Increased inflammation but similar physical composition and function in older-aged, HIV-1 infected subjects. BMC Immunol. 2015;16:43-54.
13. Cihlar T, Fordyce M. Current status and prospects of HIV treatment. Curr Opin Virol. 2016;18:50–6.
14. Reig M, Mariño Z, Perelló Ch, Iñarrairaegui M, Ribeiro A, Lens S, et al. Unexpected early tumor recurrence in patients with hepatitis C virus -related hepatocellular carcinoma undergoing interferon-free therapy: a note of caution. J Hepatol. 2016;65(4):719-26.
15. Nsight Start Study Group, Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, et al. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373:795-807.
16. Chastain DB, Henderson H, Stover KR. Epidemiology and management of antiretroviral-associated cardiovascular disease. Open AIDS J. 2015;9: 23-37.
17. Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents [citado 15/02/2018]. Disponible en: https://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf

Downloads

Published

2018-10-09

How to Cite

1.
Mendo Alcolea N, Mesa Perez E de J, Neyra Barrios R, Berenguer Gournaluses L, Nieto Muñiz G. Adverse reactions to antirretroviral drugs in patients with the human inmunodeficiency virus. MEDISAN [Internet]. 2018 Oct. 9 [cited 2025 Jun. 2];22(8). Available from: https://medisan.sld.cu/index.php/san/article/view/2237

Issue

Vol. 22 No. 8 (2018): MEDISAN

Section

Original Articles

License

All the articles can be downloaded or read for free. The journal does not charge any amount of money to the authors for the reception, edition or the publication of the articles, making the whole process completely free. Medisan has no embargo period and it is published under the license of Creative Commons, International Non Commercial Recognition 4.0, which authorizes the copy, reproduction and the total or partial distribution of the articles in any format or platform, with the conditions of citing the source of information and not to be used for profitable purposes.